

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waiver under Section 712(c)(2)(B) and 18 U.S.C. §208(b)(3)

Maha Hussain, M.D.

Committees: Oncologic Drugs Advisory Committee

Meeting Date: December 5, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to discussions of supplemental BLA 125085/91, Avastin (bevacizumab), Genetech, Inc., proposed indication, in combination with paclitaxel, for the treatment of patients who have not received chemotherapy for their locally recurrent or metastatic, HER2 negative breast cancer, I am eligible to receive a waiver under Section 712(c)(2)(B) and 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Stock	Sponsor	Valued between \$5,001 and \$25,000
Stock	2 Competing Firms	Valued at less than \$5,001 per firm
Stock	4 Competing Firms	Valued between \$5,001 and \$25,000 per firm
Unrelated consulting	Competing firm	Less than \$10,001 per year
Study of a competing product for unrelated indication	Competing firm	Between \$100,001 and \$300,000 per year

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of these interests the waiver is not valid.

_____/S/
Signature of SGE

_____/10/23/07
Date